- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00470743
Comparing Ibuprofen And Indomethacin For The Treatment Of The Patent Ductus Arteriosus in Very Premature Babies
A Randomised Controlled Trial Comparing Ibuprofen And Indomethacin For The Treatment Of The Patent Ductus Arteriosus In Very Premature Infants
Study Overview
Status
Intervention / Treatment
Detailed Description
According to Very Low Birth Weight (VLBW) High Risk Registration database in KKWCH, a hemodynamically significant patent ductus arteriosus (PDA) is a common problem in very premature infants born at a gestational age of 29 weeks and under, with more than 50% of them needing indomethacin treatment for closure of the PDA.
Prostaglandins play a major role in keeping the ductus patent . Indomethacin, because of its anti-prostaglandin effect via inhibition of the prostaglandin forming cyclo-oxygenase enzymes, has been used to medically close the PDA since the 1970s. Concerns with this drug relate to its effect on cerebral, renal and gastrointestinal blood flow. Necrotising enterocolitis (NEC), gastrointestinal perforation, gastrointestinal bleeding, transient or permanent renal impairment and reduced cerebral blood flow have been associated with indomethacin.
Ibuprofen treatment for PDA have been reported in the 1990s. It is as effective as indomethacin in closing the PDA. It is potentially better than indomethacin because regional blood flows were not affected. The few trials that have been done comparing intravenous ibuprofen and indomethacin involved mainly heavier very low birth weight (VLBW) infants. In a New England Journal of Medicine editorial on this subject, Clyman pointed out the need for trials involving the very immature infants to look at efficacy and safety.
The main obstacle for ibuprofen use in premature infants is the absence of a commercially available intravenous preparation. In our proposed trial a new i.v. ibuprofen preparation manufactured by Cumberland Pharmaceuticals (Nashville, Tennessee) will be used.
A Cochrane systematic review on ibuprofen for the treatment of PDA in premature infants concluded that it performed with the same effectiveness when compared to indomethacin. There was a significant decrease in the incidence of oliguria in the ibuprofen arm, with a higher risk of chronic lung disease at 28 days of life (borderline statistical significance), but not at 36 weeks.There is no biologically plausible explanation for the latter effect and this could be attributed to chance in view of this, plus the weak statistical proof. The other problem with this review was that it included trials where enteral ibuprofen was used, and this route is clearly impractical in the very premature infants which we plan to study because of the unpredictable absorption from the immature gut and their general intolerance to feeding at such an early age. The concern regarding pulmonary hypertension with the prophylactic use of ibuprofen also should not apply to our planned study where the time of administration of the drugs will be around 24 hours of age.
The potential benefits stemming from ibuprofen's biological advantage over indomethacin will be reduction in the rates of oliguria, gastrointestinal bleeding, NEC and gastrointestinal perforation. NEC and gastrointestinal perforation are conditions with serious morbidities and usually result in prolonged hospital stay and poorer neurodevelopmental outcome for the affected infants. A better drug could lead to cost savings.
Neurosensory impairment is an important outcome to monitor because indomethacin reduces cerebral blood flow. This point was also emphasized in the Cochrane systematic review mentioned above. However this will be the subject of another proposal in view of the significant additional budget needed.
The objective of the trial is to compare, the the safety and efficacy of intravenous ibuprofen treatment for the closure of the patent ductus arteriosus diagnosed via 2D echocardiography in very premature babies born under 29 weeks of gestation, with traditional therapy indomethacin.
The primary outcome measure will be the incidence of oliguria and gastric bleeding within one week after the 1st dose of treatment
Study Type
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Singapore, Singapore, 229899
- KK Women's and Children's Hospital / National University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Infants <29 weeks gestation with a PDA diameter of >= 1.5 mm on 2Dechocardiogram
- Parental written informed consent - Parent agrees to the subject's participation in the study as indicated by parent's signature on the consent form
- Parent is willing to comply with procedures/treatment and is able to keep to scheduled study assessments
Exclusion criteria:
- Major congenital malformations in the opinion of the investigator
- Necrotising enterocolitis
- Gastrointestinal Perforation
- Systemic illness other than PDA, not fit for the trial in the opinion of the investigator
- The parent is in the opinion of the investigator, mentally or legally incapacitated
- The parent is unwilling/unable to comply to study procedures
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ibuprofen
Compare ibuprofen
|
|
Placebo Comparator: Normal saline
Compared against ibuprofen -- placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of oliguria and gastric bleeding
Time Frame: within one week of treatment
|
within one week of treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
PDA closure rates after medical treatment at time of discharge from hospital
Time Frame: after 1 to 2 courses of treatment
|
after 1 to 2 courses of treatment
|
Need for repeat of the second course of medication
Time Frame: 48 hrs after 3rd dose of treatment
|
48 hrs after 3rd dose of treatment
|
Need for surgical closure
Time Frame: after 1 to 2 courses of treatment
|
after 1 to 2 courses of treatment
|
In-hospital mortality
Time Frame: while in-hospital
|
while in-hospital
|
Creatinine >140umol/L within one week after the 1st dose of treatment
Time Frame: one week after 1st dose of treatment
|
one week after 1st dose of treatment
|
Hyponatremia within one week after the 1st dose of treatment
Time Frame: one week after 1st dose of treatment
|
one week after 1st dose of treatment
|
Gastrointestinal perforation within one week after the 1st dose of treatment
Time Frame: within one week after the 1st dose of treatment
|
within one week after the 1st dose of treatment
|
Necrotising enterocolitis within one week after the 1st dose of treatment
Time Frame: within one week after the 1st dose of treatment
|
within one week after the 1st dose of treatment
|
Worst grade of IVH by Day 28 of life
Time Frame: Day 28 of life
|
Day 28 of life
|
Pulmonary hypertension within 48hrs after 1st dose of treatment
Time Frame: within 48hrs after 1st dose of treatment
|
within 48hrs after 1st dose of treatment
|
Chronic lung disease
Time Frame: Day 28 and corrected age of 36 weeks post-menstrual age
|
Day 28 and corrected age of 36 weeks post-menstrual age
|
Cystic periventricular leukomalacia at day 28 of life and at term
Time Frame: Day 28 of life and term corrected age
|
Day 28 of life and term corrected age
|
Retinopathy of prematurity (Worst grade)
Time Frame: Within hospitalization
|
Within hospitalization
|
Collaborators and Investigators
Investigators
- Principal Investigator: Quek Bin Huey, MMed MRCP, KK Women's and Children's Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Congenital Abnormalities
- Body Weight
- Heart Defects, Congenital
- Cardiovascular Abnormalities
- Birth Weight
- Ductus Arteriosus, Patent
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Reproductive Control Agents
- Gout Suppressants
- Tocolytic Agents
- Ibuprofen
- Indomethacin
Other Study ID Numbers
- SQPDA02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ductus Arteriosus, Patent
-
PFM Medical, IncBright Research PartnersCompleted
-
Abbott Medical DevicesCompletedPatent Ductus Arteriosus (PDA)United States
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaCompletedPatent Ductus Arteriosus | Patent Ductus Arteriosus After Premature Birth | Patent Ductus Arteriosus - Delayed ClosureItaly, United Kingdom
-
Ankara UniversityCompletedPatent Ductus Arteriosus in Preterm InfantsTurkey
-
Nada YoussefCompletedPatent Ductus Arteriosus After Premature Birth | Patent Ductus Arteriosus Conservative ManagementEgypt
-
Abbott Medical DevicesNo longer availablePatent | Ductus | Arteriosus
-
University of FlorenceCompletedDuctus Arteriosus, PatentItaly
-
National Taiwan University HospitalCompletedPatent Ductus Arteriosus
-
Rambam Health Care CampusCompletedDuctus Arteriosus, PatentIsrael
-
Soha mahmoud Hussien mahdyAssiut UniversityNot yet recruiting
Clinical Trials on Indomethacin
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...Completed
-
Indiana UniversityMedical University of South Carolina; Beth Israel Deaconess Medical Center; University... and other collaboratorsCompletedPost-ERCP PancreatitisUnited States
-
Air Force Military Medical University, ChinaCompletedPost-ERCP Acute PancreatitisChina
-
Azienda Unità Sanitaria Locale Reggio EmiliaRecruiting
-
Pontificia Universidad Catolica de ChileUnknownPremature Birth | Electroencephalography | Regional Blood FlowChile
-
Iroko Pharmaceuticals, LLCCompletedPain, PostoperativeUnited States
-
Moti Lal Nehru Medical CollegeRecruiting
-
First People's Hospital of HangzhouCompletedPost-ERCP Pancreatitis | Pancreatitis, Acute NecrotizingChina
-
IPCA Laboratories Ltd.Completed
-
Imperial College LondonWexham GI TrustCompleted